NASDAQ:BMRN BioMarin Pharmaceutical (BMRN) Stock Price, News & Analysis → See this before next week's Fed meeting (From Stansberry Research) (Ad) Free BMRN Stock Alerts $81.28 -9.92 (-10.88%) (As of 11:39 AM ET) Add Compare Share Share Today's Range$81.00▼$86.7850-Day Range$83.81▼$92.2252-Week Range$76.02▼$99.56Volume4.12 million shsAverage Volume1.38 million shsMarket Capitalization$15.34 billionP/E Ratio92.36Dividend YieldN/APrice Target$107.61 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get BioMarin Pharmaceutical alerts: Email Address BioMarin Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.63 Rating ScoreUpside/Downside32.5% Upside$107.61 Price TargetShort InterestHealthy1.96% of Shares Sold ShortDividend StrengthN/ASustainability-2.93Upright™ Environmental ScoreNews Sentiment0.38Based on 33 Articles This WeekInsider TradingSelling Shares$9.06 M Sold Last QuarterProj. Earnings Growth50.27%From $1.85 to $2.78 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.90 out of 5 starsMedical Sector75th out of 907 stocksPharmaceutical Preparations Industry24th out of 422 stocks 4.3 Analyst's Opinion Consensus RatingBioMarin Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on 12 buy ratings, 7 hold ratings, and no sell ratings.Amount of Analyst CoverageBioMarin Pharmaceutical has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.96% of the outstanding shares of BioMarin Pharmaceutical have been sold short.Short Interest Ratio / Days to CoverBioMarin Pharmaceutical has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioMarin Pharmaceutical has recently increased by 20.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBioMarin Pharmaceutical does not currently pay a dividend.Dividend GrowthBioMarin Pharmaceutical does not have a long track record of dividend growth. Previous Next 3.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBioMarin Pharmaceutical has received a 35.96% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Galsulfase", "Laronidase", and "Cerliponase alfa" products. See details.Environmental SustainabilityThe Environmental Impact score for BioMarin Pharmaceutical is -2.93. Previous Next 1.9 News and Social Media Coverage News SentimentBioMarin Pharmaceutical has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for BioMarin Pharmaceutical this week, compared to 7 articles on an average week.Search InterestOnly 8 people have searched for BMRN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added BioMarin Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -79% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioMarin Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,062,967.00 in company stock.Percentage Held by InsidersOnly 1.84% of the stock of BioMarin Pharmaceutical is held by insiders.Percentage Held by Institutions98.71% of the stock of BioMarin Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for BioMarin Pharmaceutical are expected to grow by 50.27% in the coming year, from $1.85 to $2.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioMarin Pharmaceutical is 92.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.32.Price to Earnings Ratio vs. SectorThe P/E ratio of BioMarin Pharmaceutical is 92.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 174.82.Price to Earnings Growth RatioBioMarin Pharmaceutical has a PEG Ratio of 1.70. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioBioMarin Pharmaceutical has a P/B Ratio of 3.09. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About BioMarin Pharmaceutical Stock (NASDAQ:BMRN)BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.Read More BMRN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRN Stock News HeadlinesApril 16, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director Jean Jacques Bienaime Sells 20,000 SharesApril 13, 2024 | insidertrades.comBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CAO Erin Burkhart Sells 2,286 SharesApril 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 2, 2024 | insidertrades.comInsider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 24,602 Shares of StockApril 25, 2024 | finance.yahoo.comQ1 2024 Biomarin Pharmaceutical Inc Earnings CallApril 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionApril 25, 2024 | finance.yahoo.comBiomarin Pharmaceutical Inc (BMRN) Q1 2024 Earnings Call Transcript Highlights: Strong Growth ...April 25, 2024 | americanbankingnews.comBioMarin Pharmaceutical Sees Unusually High Options Volume (NASDAQ:BMRN)April 25, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItSee this before next week's Fed Meeting Thousands of investing ideas come across his desk every year… But Doc Eifrig just revealed THIS ONE "will go down as one of the smartest and most lucrative financial moves of the decade." (Last time we shared this, it led to a 995% gain.)April 24, 2024 | investing.comUBS maintains Buy on BioMarin, sees Voxzogo potentialApril 24, 2024 | finance.yahoo.comBioMarin Reports Record Financial Results for the First Quarter 2024April 24, 2024 | msn.comBMRN Stock Earnings: Biomarin Pharmaceutical Beats EPS, Misses Revenue for Q1 2024April 24, 2024 | seekingalpha.comBioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call PresentationApril 24, 2024 | markets.businessinsider.comBiomarin Pharmaceutical Inc. Q1 Profit Increases, beats estimatesApril 24, 2024 | sfgate.comBioMarin: Q1 Earnings SnapshotApril 24, 2024 | finance.yahoo.comBioMarin Pharmaceutical Inc. (BMRN) Q1 2024 Earnings: Surpasses Revenue and EPS EstimatesApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed on BioMarin Amid Voxzogo Success and Promising Growth OutlookApril 24, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Biogen (BIIB) and BioMarin Pharmaceutical (BMRN)April 22, 2024 | finance.yahoo.comBioMarin Pharmaceutical Investors to Focus Q1 on Strategic Review, Cost-Cutting Measures, UBS SaysApril 19, 2024 | nasdaq.comGuru Fundamental Report for BMRN - Benjamin GrahamApril 19, 2024 | americanbankingnews.comFY2025 EPS Estimates for BioMarin Pharmaceutical Inc. Cut by Leerink Partnrs (NASDAQ:BMRN)April 17, 2024 | finance.yahoo.comBioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?April 17, 2024 | americanbankingnews.comBioMarin Pharmaceutical (BMRN) Set to Announce Earnings on WednesdayApril 17, 2024 | investing.comBiomarin CEO sells over $3.6m in company stockApril 13, 2024 | ca.investing.comMerck, Vertex could beat expectations despite more subdued 1Q biopharma earnings anticipated: BofAApril 12, 2024 | finance.yahoo.comInsider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...April 10, 2024 | prnewswire.comBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ETSee More Headlines Receive BMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioMarin Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:BMRN CUSIP09061G10 CIK1048477 Webwww.bmrn.com Phone(415) 506-6700Fax415-382-7889Employees3,401Year Founded1997Price Target and Rating Average Stock Price Target$107.61 High Stock Price Target$185.00 Low Stock Price Target$78.00 Potential Upside/Downside+18.0%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio103.64 Forward P/E Ratio49.30 P/E Growth1.65Net Income$167.65 million Net Margins6.93% Pretax Margin7.79% Return on Equity5.01% Return on Assets3.64% Debt Debt-to-Equity Ratio0.12 Current Ratio2.51 Quick Ratio1.57 Sales & Book Value Annual Sales$2.42 billion Price / Sales7.11 Cash Flow$1.82 per share Price / Cash Flow50.02 Book Value$26.29 per share Price / Book3.47Miscellaneous Outstanding Shares188,730,000Free Float185,261,000Market Cap$17.21 billion OptionableOptionable Beta0.31 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Brian R. Mueller (Age 50)CFO & Executive VP Comp: $1.15MMr. George Eric Davis (Age 53)Executive VP, Chief Legal Officer, General Counsel & Secretary Comp: $1.23MMr. Jeffrey Robert Ajer (Age 62)Executive VP & Chief Commercial Officer Comp: $1.18MDr. Henry J. Fuchs M.D. (Age 66)Ph.D., President of Worldwide Research & Development Comp: $1.49MMr. Alexander Hardy (Age 55)President, CEO & Director Ms. Erin BurkhartGroup VP & Chief Accounting OfficerDr. Kevin Eggan Ph.D.Chief Scientific Officer & Senior VP of Research and Early DevelopmentTraci McCartyGroup Vice President of Investor RelationsMs. Humaira SerajuddinSenior VP & Chief Marketing OfficerMs. Amy WiremanExecutive VP & Chief People OfficerMore ExecutivesKey CompetitorsAlnylam PharmaceuticalsNASDAQ:ALNYMyoKardiaNASDAQ:MYOKUnited TherapeuticsNASDAQ:UTHRReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsSummit Financial LLCSold 931 shares on 4/25/2024Ownership: 0.031%Assenagon Asset Management S.A.Sold 13,842 shares on 4/24/2024Ownership: 0.002%Simplicity Wealth LLCBought 2,958 shares on 4/24/2024Ownership: 0.002%Rice Hall James & Associates LLCSold 692 shares on 4/23/2024Ownership: 0.015%IFM Investors Pty LtdBought 158 shares on 4/22/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions BMRN Stock Analysis - Frequently Asked Questions Should I buy or sell BioMarin Pharmaceutical stock right now? 19 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last twelve months. There are currently 7 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMRN shares. View BMRN analyst ratings or view top-rated stocks. What is BioMarin Pharmaceutical's stock price target for 2024? 19 Wall Street analysts have issued 1 year price targets for BioMarin Pharmaceutical's stock. Their BMRN share price targets range from $78.00 to $185.00. On average, they expect the company's share price to reach $107.61 in the next twelve months. This suggests a possible upside of 32.5% from the stock's current price. View analysts price targets for BMRN or view top-rated stocks among Wall Street analysts. How have BMRN shares performed in 2024? BioMarin Pharmaceutical's stock was trading at $96.42 at the beginning of 2024. Since then, BMRN shares have decreased by 15.7% and is now trading at $81.24. View the best growth stocks for 2024 here. Are investors shorting BioMarin Pharmaceutical? BioMarin Pharmaceutical saw a increase in short interest in April. As of April 15th, there was short interest totaling 3,690,000 shares, an increase of 20.6% from the March 31st total of 3,060,000 shares. Based on an average daily volume of 1,410,000 shares, the short-interest ratio is currently 2.6 days. View BioMarin Pharmaceutical's Short Interest. How were BioMarin Pharmaceutical's earnings last quarter? BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its earnings results on Thursday, February, 22nd. The biotechnology company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.05. The biotechnology company had revenue of $646.21 million for the quarter, compared to the consensus estimate of $639.53 million. BioMarin Pharmaceutical had a net margin of 6.93% and a trailing twelve-month return on equity of 5.01%. The company's quarterly revenue was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.11 EPS. What ETFs hold BioMarin Pharmaceutical's stock? ETFs with the largest weight of BioMarin Pharmaceutical (NASDAQ:BMRN) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Global X Genomics & Biotechnology ETF (GNOM), First Trust NYSE Arca Biotechnology Index Fund (FBT), Goldman Sachs Future Health Care Equity ETF (GDOC), VanEck Biotech ETF (BBH), Motley Fool Mid-Cap Growth ETF (TMFM), First Trust Innovation Leaders ETF (ILDR) and BlackRock Future Health ETF (BMED). What guidance has BioMarin Pharmaceutical issued on next quarter's earnings? BioMarin Pharmaceutical updated its FY 2024 earnings guidance on Wednesday, April, 24th. The company provided earnings per share guidance of 2.750-2.950 for the period, compared to the consensus estimate of 1.650. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion. What is Jean-Jacques Bienaimé's approval rating as BioMarin Pharmaceutical's CEO? 228 employees have rated BioMarin Pharmaceutical Chief Executive Officer Jean-Jacques Bienaimé on Glassdoor.com. Jean-Jacques Bienaimé has an approval rating of 94% among the company's employees. This puts Jean-Jacques Bienaimé in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at BioMarin Pharmaceutical to a friend. What other stocks do shareholders of BioMarin Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), Vertex Pharmaceuticals (VRTX), (KITE) (KITE) and Freeport-McMoRan (FCX). Who are BioMarin Pharmaceutical's major shareholders? BioMarin Pharmaceutical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.25%), AMI Asset Management Corp (0.18%), Allspring Global Investments Holdings LLC (0.05%), Summit Financial LLC (0.03%), IFM Investors Pty Ltd (0.02%) and Rice Hall James & Associates LLC (0.02%). Insiders that own company stock include Brian Mueller, Charles Greg Guyer, Dennis Slamon, Erin Burkhart, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Mark J Alles, Richard A Meier and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of BioMarin Pharmaceutical? Shares of BMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BMRN) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profits“The Biggest Bubble of All Time” – Here’s What to Do.Chaikin Analyticstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioMarin Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
